RE:RE:Valeant soon to become $1 like Concordia health Deutsche Bank reiterated its $18usd price target on the drug stock -- territory not seen since late November -- saying it is "warming up" to the shares. Valeant Pharmaceuticals is now up 62% since its multi-year low of $8.31 from April 24, and VRX options traders have been buying to open calls over puts at a faster-than-usual clip. VRX stock has a 10-day call/put volume ratio of 3.30 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which ranks in the 92nd annual percentile.